Research programme: alcohol dehydrogenase inhibitors - Gilead Sciences

Drug Profile

Research programme: alcohol dehydrogenase inhibitors - Gilead Sciences

Alternative Names: CVT-10216

Latest Information Update: 15 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CV Therapeutics
  • Developer Gilead Sciences
  • Class Benzoic acids; Benzopyrans; Sulfonamides
  • Mechanism of Action Aldehyde dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alcoholism

Most Recent Events

  • 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top